Key Drivers
- Strong liquidity
- Negative cash flow
- Rich valuation
AIAI Summary
GKOS has shifted from a pipeline story to a commercialization execution test: the Epioxa J-code and iDose TR provide real launch leverage, but the rich valuation now depends on proving that strong revenue growth can translate into durable operating cash flow and operating margin expansion before cash burn and expenses catch up.
Price Chart
Financial Metrics
Deep Analysis
Research tool. Not personalized advice.
Fundamental Analysis
Key Financial Insights:
- •Strong liquidity
- •Negative cash flow
- •Rich valuation
GKOS has a strong, low-leverage balance sheet, but persistent losses, negative cash flow, and a rich valuation keep the stock risky despite improved gross margins.
Price Behavior
Key Price Behavior Insights:
- •Trend intact
- •Support holding
- •Quick rebound
GKOS remains in a strong uptrend over the last month, breaking above its late-June high near $144.42, but after a sharp run it needs to hold the $131-$138 support zone to keep the bullish setup intact.
Sharp drop from $144.42 to $137.57 before a quick rebound
Sentiment & News
Key News Insights:
- •iDose TR momentum
- •Epioxa launch
- •GLK-321 progress
Glaukos is sustaining commercial momentum from iDose TR and Epioxa while advancing its pipeline with GLK-321 enrollment completion, though reimbursement and competition remain key execution risks.
The updates are modestly positive for GKOS, reinforcing growth visibility while adding credibility to its longer-term ophthalmic pipeline
Similar Companies in Healthcare
Other companies in the same sector with AI ratings